GenSight vet Combal grabs $40M from Novartis, Roche group for second-wave gene therapy biotech
Up until some months ago, Jean-Philippe Combal had been the COO at Paris-based GenSight Biologics, focused on a closely-watched late-stage study of an experimental gene therapy for Leber’s Hereditary Optic Neuropathy (or LHON), a rare mitochondrial disease that destroys vision. But in a quick leap, he’s now jumped ship, leaving CEO Bernard Gilly’s crew and launching a new wave therapy startup of his own that has attracted about $40 million in startup cash.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.